An observational study in Malignant Tumors, sponsored by Nanfang Hospital, Southern Medical University. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.
Sponsored by Nanfang Hospital, Southern Medical University · Observational
This study is a single-center observational investigation aimed at systematically exploring the key molecular features influencing the prognosis of malignant tumors by integrating multidimensional clinical information with multi-omics molecular data. The goal is to provide a critical scientific basis for constructing precise prognostic prediction models, identifying potential therapeutic targets, and optimizing clinical treatment strategies. The study plans to consecutively enroll adult patients with histologically confirmed malignant tumors who received antitumor therapy at our hospital between January 2017 and December 2025. Clinical data (including demographic characteristics, tumor pathology information, treatment histories, and survival follow-up data) will be systematically collected from electronic medical records. Additionally, tumor tissue or blood samples will be obtained from the patients for sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry analysis to comprehensively characterize the genomic features, immune microenvironment, and cellular heterogeneity of the tumors.
9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.
This study's planned enrollment of 500 is above the median of 204 across 1,683 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Nanfang Hospital, Southern Medical University is the lead sponsor of 480 studies on the registry; 212 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients with pathologically confirmed malignant tumors.
Inclusion Criteria:
Exclusion Criteria:Patients deemed by the investigator to be unsuitable for participation in this study.
Drug: Immunotherapy Therapy
Radiation: Radiation Therapy
Procedure: Radical surgery
Patients receiving immunotherapies such as immune checkpoint inhibitors. Immunotherapy can be administered as first-line or subsequent treatment, or as part of combination therapy, integrated with modalities such as surgery, chemotherapy, radiotherapy, and targeted therapy.
Patients for whom radiotherapy is the primary or a significant component of their treatment. Radiotherapy may be administered with curative, adjuvant, or palliative intent, and can be given alone or in combination with surgery, chemotherapy, targeted therapy, immunotherapy, etc.
Patients undergoing curative tumor resection as their primary treatment modality. Surgery may be performed with or without neoadjuvant/adjuvant chemotherapy, radiotherapy, targeted therapy, or immunotherapy.
Overall Survival (OS)
The time from the start of treatment to death from any cause. Patients who are alive at the last follow-up are censored.
Time frame: From date of treatment initiation until date of death or last follow-up, assessed up to 5 years.
Progression-Free Survival (PFS)
The time from the start of treatment to the first documented disease progression (per RECIST criteria) or death from any cause, whichever occurs first.
Time frame: From date of treatment initiation until date of progression or death, assessed up to 5 years.
Pathological Complete Response (pCR)
The absence of residual invasive cancer in the resected tumor specimen and lymph nodes after neoadjuvant therapy, as determined by histopathological evaluation.
Time frame: At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy.
Major Pathologic Response (MRP)
The presence of ≤10% residual viable tumor cells in the resected tumor specimen after neoadjuvant therapy, assessed by pathological examination.
Time frame: At the time of surgery following neoadjuvant treatment, typically within 4-6 weeks after completion of therapy.
Plan to share: Undecided
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Nanfang Hospital, Southern Medical University